跳至主要内容
临床试验/NCT04096898
NCT04096898Unknown不适用

Clinical Trial to Determine Whether Senofilcon A Lenses Provide Relief of Symptoms and Signs in Patients With Moderate to Severe Dry Eye Disease

University of Illinois at Chicago2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2018年4月23日最近更新:
适应症

试验速览

阶段
不适用
入组人数
32
试验地点
2
主要终点
Ocular Surface Disease Index (OSDI)

研究概览

简要总结

A clinical trial using Senofilcon A daily lenses in the treatment of moderate to severe dry eye. This a comparison between signs and symptoms prior to and during treatment.

详细描述

32 patients with moderate to severe dry eye will be enrolled in this short-term proof of concept study to determine the efficacy in using soft lenses made of Senofilcon A in reducing signs and symptoms.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of moderate to severe dry eye associated with either Graft-versus-host disease (GVHD), Sjogren syndrome, idiopathic dry eyes, or minimal limbal cell deficiency
  • A baseline Schirmer tear test (1) of less than 5 mm at 5 minutes without anesthesia
  • Have a visual analog score for comfort of 50 or less (scale of 1-100, with 100 meaning perfect ocular comfort and 1 meaning severe ocular pain)
  • Ability or the resources to insert and remove the study lenses
  • An OSDI score greater than 42
  • A willingness to sign an informed consent

排除标准

  • No dry eyes or mild dry eyes
  • A baseline Schirmer tear test (1) of greater than 5 mm of wetting at 5 minutes
  • Dry eye comfort score of greater than 50 on a visual analog scale
  • Unable to insert or remove the study lenses (or have a family member do so)
  • Have an OSDI score less than 42
  • Has been diagnosed with neurotrophic keratopathy in either eye
  • Unwilling to enroll in the study, and unwilling to provide signed informed consent to participate in the study

结局指标

主要结局

Ocular Surface Disease Index (OSDI)

时间窗: 2 weeks

Patient questionaire

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Timothy T. McMahon, OD

Dr. Timothy T. McMahon

University of Illinois at Chicago

研究点 (2)

Loading locations...

相似试验